{"id":"isis-fgfr4rx","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ISIS-FGFR4RX is an antisense oligonucleotide that specifically targets fibroblast growth factor receptor 4 (FGFR4) to reduce its expression and activity.","oneSentence":"Antisense oligonucleotide targeting fibroblast growth factor receptor 4","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:02:50.339Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors"}]},"trialDetails":[{"nctId":"NCT02476019","phase":"PHASE2","title":"A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2015-06","conditions":"Obesity","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ISIS 463588"],"phase":"phase_2","status":"active","brandName":"ISIS-FGFR4RX","genericName":"ISIS-FGFR4RX","companyName":"Ionis Pharmaceuticals, Inc.","companyId":"ionis-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antisense oligonucleotide targeting fibroblast growth factor receptor 4 Used for Solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}